OMC
SPRO icon

OUP Management Company’s Spero Therapeutics SPRO Stock Holding History

OUP Management Company’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$301K Hold
249,070
– – 0.68% 10
2023
Q2 		$361K Hold
249,070
– – 0.62% 11
2023
Q1 		$361K Hold
249,070
– – 0.72% 13
2022
Q4 		$431K Hold
249,070
– – 0.7% 13
2022
Q3 		$498K Hold
249,070
– – 0.78% 14
2022
Q2 		$185K Hold
249,070
– – 0.25% 14
2022
Q1 		$2.17M Hold
249,070
– – 1.65% 12
2021
Q4 		$3.99M Buy
+249,070
New +$3.96M 1.8% 14

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

OUP Management Company's SPRO Position: Q3 2023 in Review

OUP Management Company held its Spero Therapeutics (SPRO) position steady in Q3 2023 at 249,070 shares worth $301K. The position accounts for 0.68% of the portfolio, ranked #10.

OUP Management Company first reported a position in SPRO in Q4 2021 and has held it in 8 quarters since. The position peaked at $3.99M in Q4 2021. 54 funds tracked by Wall St. Rank hold SPRO as of Q3 2023.

  • OUP Management Company held 249,070 shares of Spero Therapeutics worth $301K as of Q3 2023.
  • OUP Management Company left its Spero Therapeutics share count unchanged in Q3 2023.
  • Spero Therapeutics made up 0.68% of OUP Management Company's portfolio in Q3 2023, its #10 holding.
  • OUP Management Company first reported a position in Spero Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • OUP Management Company's Spero Therapeutics position peaked at $3.99M in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2023.

Based on OUP Management Company's 13F filing for Q3 2023, filed 9 Nov 2023.